Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
Developer of life sciences technology intended to develop highly effective and differentiated treatments for cystic fibrosis. The company is developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with cystic fibrosis, enabling patients with best-in-class efficacy and reach and long-term benefit for people with cystic fibrosis.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated the best-in-class platform and initiated multiple programs across different disease areas.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
Curie Therapeutics is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted radiopharmaceuticals that are both safe and effective. Curie's radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. The company’s pipeline spans multiple therapeutic areas.
Versanis Bio focuses on developing therapies to address health issues prevalent among older adults, particularly obesity and its associated complications. The company's lead product, bimagrumab, is a human monoclonal antibody that targets activin type II receptors, effectively blocking the binding of ligands such as activin A and myostatin. This treatment has undergone extensive clinical evaluation, with over 1,500 participants in various controlled trials previously conducted by Novartis. Bimagrumab has shown the ability to induce significant fat loss without compromising lean muscle mass, while also improving important cardiometabolic markers such as HbA1c. Through its innovative approach, Versanis Bio aims to help overweight and obese adults achieve and maintain a healthier body composition.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.
Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.
Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on advancing AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed to treat pulmonary arterial hypertension (PAH). This innovative delivery method targets diseased lung tissues directly, minimizing systemic side effects often associated with traditional therapies. Founded in 2018 and initially incubated by RA Capital Management, Aerovate aims to provide meaningful improvements to the lives of those affected by these serious conditions.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Remix Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on the research and development of innovative small molecule therapies that reprogram RNA processing to address various diseases. Founded in 2018, the company utilizes a biology platform to identify and prioritize therapeutic targets within RNA processing, aiming to tackle previously undruggable disease drivers. Its REMseq platform assists in validating these targets and optimizing chemical compounds for potential treatments. By analyzing patterns in RNA processing, Remix Therapeutics seeks to modulate gene expression, thereby enabling healthcare providers to correct or enhance genetic messages at their source, ultimately aiming to provide new approaches for treating diseases.
Third Harmonic Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for severe allergies and inflammation. The company is focused on creating first-in-class oral small-molecule inhibitors targeting the KIT receptor, which plays a crucial role in the survival and function of mast cells—key immune cells involved in allergic responses. Its lead product candidate, THB001, is designed to provide selective inhibition of KIT, while another candidate, THB335, aims to address multiple mast cell-driven inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. Through its research and development efforts, Third Harmonic Bio seeks to advance the management of inflammatory diseases, enhancing patient outcomes and quality of life.
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
NIR is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2017 and headquartered in Boston, Massachusetts.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017, the company aims to address high unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage that can lead to severe complications. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate is designed to restore metabolic balance by reducing liver fat and suppressing inflammation and fibrosis, thereby potentially halting the progression of NASH. The development of AKR-001 builds upon extensive research into FGF21 biology, positioning it as a promising treatment option in a field lacking approved therapies.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases, particularly through immuno-oncology. Established in 2016 and headquartered in Shanghai, China, the company employs two patented transgenic mouse platforms for generating fully human monoclonal antibodies and heavy chain only antibodies, enabling the creation of bispecific antibodies and other therapeutic compounds. Harbour BioMed's development pipeline includes products targeting various conditions, such as autoimmune diseases and respiratory infections. The company also licenses its antibody platforms to other firms and academic institutions via its Harbour Antibodies subsidiary. It has formed strategic collaborations with several notable organizations, including The Wistar Institute and WuXi Biologics, and maintains partnerships with various biopharmaceutical companies. With operations in Cambridge, Massachusetts, and antibody platform innovation in Rotterdam, the Netherlands, Harbour BioMed is positioned to enhance drug discovery and development across multiple global markets.
Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Disarm Therapeutics is a biotechnology company focused on developing disease-modifying therapeutics for patients suffering from neurological diseases characterized by axonal degeneration. Founded in 2016 and based in Cambridge, Massachusetts, the company aims to prevent axon loss and address conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Its innovative approach allows for the treatment of acute diseases affecting the central, ocular, and peripheral nervous systems. As of October 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.
Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.
Gemini Therapeutics, Inc. is a precision medicine company established in 2015 and based in Cambridge, Massachusetts. The company specializes in developing therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini's approach focuses on addressing genetically-defined conditions by creating therapeutic candidates that target specific molecular abnormalities prevalent in patients with significant clinical needs. Their diverse pipeline features a range of innovative treatment modalities, including monoclonal antibodies, recombinant proteins, and gene therapies. The company has secured funding from prominent life science investors and collaborates with academic institutions globally to advance its mission of delivering potentially first-in-class therapeutics.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small molecule drugs that target mTORC1, a key regulator of cellular metabolism and renewal, to treat age-related diseases. Utilizing a proprietary platform, Navitor's therapies can selectively inhibit or activate mTORC1, which plays a crucial role in cellular processes. One of its notable products, NV-5138, is an orally bioavailable small molecule designed to activate mTORC1, particularly addressing its suppression in the brain associated with depression. Additionally, the company's N-Valog program focuses on selective inhibition of mTORC1 for chronic kidney disease, with implications for other age-related conditions. Founded in 2009 and headquartered in Cambridge, Massachusetts, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway by modulating nutrient-sensing proteins, thereby addressing various metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, that specializes in a cloud-based platform designed to streamline the management of specialty medications. Founded in 2012, the company provides a secure online environment where healthcare providers, specialty pharmacies, and biopharma companies can collaborate efficiently. Its platform automates the prescription and prior authorization processes, facilitating communication among patients, physicians, and pharmacists while reducing reliance on traditional methods such as faxes and phone calls. By consolidating essential information related to specialty prescribing—including pharmacy details, payer requirements, and clinical history—the platform enhances the efficiency and transparency of healthcare delivery, particularly in the fields of pulmonary, cardiology, and gastroenterology. ZappRx operates as a subsidiary of Allscripts Healthcare Solutions, Inc. as of June 2019.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Lysosomal Therapeutics, Inc. is focused on discovering and developing small-molecule therapies aimed at treating severe neurological diseases, including Gaucher-related neurodegeneration and Parkinson’s disease. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a research strategy that capitalizes on the established connection between lysosomal disorders and neurodegenerative conditions. This approach supports the development of innovative treatment options for patients affected by movement, cognition, and overall health issues related to these diseases. By leveraging clinically validated insights, Lysosomal Therapeutics aims to create effective therapies to address the unmet medical needs in the field of neurodegeneration.
Padlock is developing medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complexes in autoimmune diseases. Padlock intends to explore the full biological and therapeutic footprint of protein deimination by PADs. Padlock was founded by scientists at The Scripps Research Institute and members of the Atlas Venture Life Sciences Team. Padlock's investors include Atlas Venture, Johnson & Johnson, and MS Ventures. Padlock is a seed company operating out of the Atlas Venture office in Cambridge MA.
Quartet Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2013. It focuses on developing innovative treatments for chronic pain and inflammation by targeting the restoration of tetrahydrobiopterin (BH4) homeostasis in neuronal and inflammatory cells. Research indicates that increased levels of BH4 play a crucial role in managing peripheral nerve dysfunction and regulating immune cells. Founded by scientists from Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne, Quartet Medicine collaborates with various research partners in Europe and Asia to advance its therapeutic approaches. The company has attracted investment from notable firms, reflecting confidence in its mission to address significant health challenges associated with chronic pain.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
PillPack, Inc. is a full-service pharmacy that specializes in medication management by sorting and delivering prescriptions in personalized packets. The company receives prescriptions from healthcare providers and organizes medications according to the prescribed dosage, ensuring that customers take the right medications at the right times. In addition to prescription medications, PillPack offers a range of health-related products, including vitamins, over-the-counter medications, inhalers, creams, and testing supplies. Founded in 2013 and headquartered in Manchester, New Hampshire, PillPack operates multiple locations across the United States. The company also engages with customers through its online magazine, Folks, which shares inspiring stories of individuals overcoming health challenges. As of September 2018, PillPack functions as a subsidiary of Amazon.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small molecule drugs that target mTORC1, a key regulator of cellular metabolism and renewal, to treat age-related diseases. Utilizing a proprietary platform, Navitor's therapies can selectively inhibit or activate mTORC1, which plays a crucial role in cellular processes. One of its notable products, NV-5138, is an orally bioavailable small molecule designed to activate mTORC1, particularly addressing its suppression in the brain associated with depression. Additionally, the company's N-Valog program focuses on selective inhibition of mTORC1 for chronic kidney disease, with implications for other age-related conditions. Founded in 2009 and headquartered in Cambridge, Massachusetts, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway by modulating nutrient-sensing proteins, thereby addressing various metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases.
Numerate, Inc., a biotechnology company, provides a drug design platform for developing small molecule therapeutics. Its platform engages in developing a pipeline of drug programs for cardiovascular, metabolic, neurodegenerative, and Alzheimer’s and Huntington’s diseases; and drug candidates that address the need for antiarrhythmic therapy for the treatment and prevention of ventricular tachycardias and fibrillation. The company was founded in 2007 and is based in San Bruno, California.
Lysosomal Therapeutics, Inc. is focused on discovering and developing small-molecule therapies aimed at treating severe neurological diseases, including Gaucher-related neurodegeneration and Parkinson’s disease. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a research strategy that capitalizes on the established connection between lysosomal disorders and neurodegenerative conditions. This approach supports the development of innovative treatment options for patients affected by movement, cognition, and overall health issues related to these diseases. By leveraging clinically validated insights, Lysosomal Therapeutics aims to create effective therapies to address the unmet medical needs in the field of neurodegeneration.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, that specializes in a cloud-based platform designed to streamline the management of specialty medications. Founded in 2012, the company provides a secure online environment where healthcare providers, specialty pharmacies, and biopharma companies can collaborate efficiently. Its platform automates the prescription and prior authorization processes, facilitating communication among patients, physicians, and pharmacists while reducing reliance on traditional methods such as faxes and phone calls. By consolidating essential information related to specialty prescribing—including pharmacy details, payer requirements, and clinical history—the platform enhances the efficiency and transparency of healthcare delivery, particularly in the fields of pulmonary, cardiology, and gastroenterology. ZappRx operates as a subsidiary of Allscripts Healthcare Solutions, Inc. as of June 2019.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, that specializes in a cloud-based platform designed to streamline the management of specialty medications. Founded in 2012, the company provides a secure online environment where healthcare providers, specialty pharmacies, and biopharma companies can collaborate efficiently. Its platform automates the prescription and prior authorization processes, facilitating communication among patients, physicians, and pharmacists while reducing reliance on traditional methods such as faxes and phone calls. By consolidating essential information related to specialty prescribing—including pharmacy details, payer requirements, and clinical history—the platform enhances the efficiency and transparency of healthcare delivery, particularly in the fields of pulmonary, cardiology, and gastroenterology. ZappRx operates as a subsidiary of Allscripts Healthcare Solutions, Inc. as of June 2019.
Harbour Antibodies BV, established in 2006 and based in Rotterdam, Netherlands, specializes in the production of antibodies and VH domains for therapeutic applications. The company utilizes advanced transgenic mouse technology to engineer mice capable of generating high affinity human antibodies. It has developed two key types of human immunoglobulin gene transgenic mice: those that produce conventional tetrameric antibodies, known as H2L2 antibodies, which consist of two heavy and two light chains, and those that generate heavy chain-only antibodies (HCAbs), which lack light chains. The availability of HCAbs allows for the generation of soluble human VH domains, facilitating the creation of innovative multi-functional molecules. Harbour Antibodies' transgenic mouse lines are accessible to licensing partners, enhancing research and development in the field of antibody therapeutics. The company operates as a subsidiary of Harbour BioMed.
Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.
CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Founded in 2011, the company specializes in cancer immunotherapy, creating antibody drugs that target immunological checkpoint control mechanisms. By harnessing the body's immune response, CoStim aims to improve therapeutic options for patients with cancer.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Annovation BioPharma
Series A in 2012
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.
Annovation BioPharma
Venture Round in 2012
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.
Arteaus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for the prevention of migraines. The company focuses on creating drugs that target calcitonin gene-related peptide (CGRP), a key molecule involved in the migraine pathway. By developing antibodies that inhibit CGRP, Arteaus aims to provide effective treatment options for individuals suffering from migraine headaches.
Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
Arteaus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for the prevention of migraines. The company focuses on creating drugs that target calcitonin gene-related peptide (CGRP), a key molecule involved in the migraine pathway. By developing antibodies that inhibit CGRP, Arteaus aims to provide effective treatment options for individuals suffering from migraine headaches.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Annovation BioPharma
Venture Round in 2011
Annovation BioPharma develops pharmaceutical products in the field of anesthesia, sedation, and sleep. The company was incorporated in 2009 and is based in Wayland, Massachusetts.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.
Nimbus Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that specializes in discovering and developing innovative small molecule therapeutics for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company employs a computational technology-driven approach to advance its diverse pipeline of drug candidates into clinical development. Its Nimbus Apollo program includes the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase, which is being investigated for treating non-alcoholic steatohepatitis and hepatocellular carcinoma, among other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, and the company aims to leverage its strategic partnerships to enhance its research and development efforts. Founded in 2009, Nimbus Therapeutics continues to focus on creating highly selective and potent medicines that address unmet medical needs.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Molecular Biometrics, Inc. is a metabolomics company based in Norwood, Massachusetts, focused on developing non-invasive methodologies for assessing biological functions in health and disease, as well as for drug discovery and development. Established in 2005, the company leverages innovative metabolomic technologies to create molecular gastronomy kits. Its applications span various fields, including reproductive health, neurodegenerative diseases such as Alzheimer's and Parkinson's, maternal-fetal medicine, pulmonary metabolism and edema, and lactate metabolism. By applying its proprietary technology, Molecular Biometrics aims to enhance the understanding and treatment of complex health issues.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
AEB's compact electron beam emitters replace thermal and chemical processes for cleaner, more efficient, lower-cost manufacturing. For industries such as pharmaceutical, medical devices, food and beverage, printing, and plastics manufacturing, AEB emitters sterilize products and packaging, improve the performance of plastics and other materials, cure inks and coatings and eliminate pollution.
InfaCare Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing treatments for neonatal and pediatric patients. Founded in 2005 and headquartered in Trevose, Pennsylvania, the company is advancing its lead product, Stanate, which is designed to treat infantile jaundice, also known as hyperbilirubinemia. Stanate is a heme oxygenase inhibitor administered via a single intramuscular injection, targeting the breakdown of heme and inhibiting bilirubin production in both term and preterm newborns. This innovative approach aims to reduce the necessity for common interventions such as phototherapy and exchange transfusions, thereby improving care for vulnerable infant populations.
Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.
NovaMed Pharmaceuticals (诺凡麦医药) is a Chinese group based on virtual integration. It is focused on complete business functions such as sales and marketing, register, circulation, manufacture, and R&D. NovaMed Pharmaceuticals was founded by senior management personnel in transnational pharmaceutical companies. The founders are professionals with broad social networks and domestic market knowledge.
Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.
Prestwick Pharmaceuticals
Venture Round in 2007
Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. The company offers products for restless legs syndrome, schizophrenia, autism, Alzheimer’s, and sleep apnea ailments. Prestwick Pharmaceuticals was founded in 2002 and is based in Washington, District of Columbia.
Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.